SCP-8549
Unknown
~
medium confidence
SCP-8549
Expected annual
$5.7M
One-time setup
$5.4M
Annual recurring
$5.2M
Personnel
34
Initial capital and facility upgrades (BSL-3 fit-out, site acquisition, decontamination infrastructure) drive one-time costs (~$5.4M); recurring costs are dominated by staffing, daily sterilization, environmental testing and R&D (~$5.17M/yr).
One-Time Capital Costs
Total: $5.4M
Annual Recurring Costs
Total: $5.2M/yr
Cost Scenarios
📊
Baseline
(baseline)
$5.2M/yr
Normal year with no major containment incidents; daily sterilization, monitoring, research and routine operations continue as budgeted.
routine_operations
environmental_monitoring
ongoing_research
🚨
Minor Incident
$5.4M/yr
Localized breach or growth detected outside the perimeter requiring perimeter expansion, extra spraying, and increased hazardous disposal.
perimeter_breach
spore_detection_outside_perimeter
localized_growth_expansion
🚨
Major Breach
$15.2M/yr
Significant spread requiring community-scale remediation, evacuation assistance, large-scale soil replacement and legal/PR response.
widespread_spore_spread
community_exposure
mass_remediation
🚨
Bsl4 Upgrade
$38.2M/yr
Determination that organism requires BSL-4-level containment and operations, triggering capital upgrade and sustained higher operating costs.
airborne_catastrophic_risk
pathogen_reclassification
regulatory_upgrade
Personnel
34 total
| Role | Count | Notes |
|---|---|---|
| Security Officer / MTF Agent | 16 | [#3] 24/7 perimeter staffing: ~12–16 guards plus supervisors (4–5 per shift, redundancy). |
| Hazmat / Decon Crew | 8 | [#4] Rotational hazmat/spray crew (6–10 personnel) performing 4 treatments/day and decontamination duties. |
| Research Scientist | 5 | [#16, #18] PI and research scientists conducting mycology, immunology, and therapeutic R&D. |
| Lab Technician | 3 | [#7, #17] Technical staff for daily sampling, sequencing runs, and lab assays. |
| Medical Officer | 2 | [#15, #18] Clinicians for isolation care, imaging, and emergency medical response under containment. |
Confidence Notes
Analyst notes provide detailed line-item ranges, but uncertainty remains around organism risk (BSL-3 vs BSL-4), frequency/severity of breaches, and long-term therapeutic development costs, producing moderate confidence.